A clinical trial has started for patients with severe asthma

Dobrobut Medical Network is recruiting patients with severe uncontrolled bronchial asthma to participate in an international Phase III clinical trial evaluating a new investigational biological medicine.

Severe uncontrolled bronchial asthma is a form of the disease in which symptoms and exacerbations persist despite ongoing treatment. These patients often require repeated courses of systemic corticosteroids, experience significant limitations in daily life, and face an increased risk of hospitalization. Today, one of the most promising treatment approaches is biologic therapy, which targets the underlying mechanisms of the disease and may help achieve better asthma control.

“For people living with severe uncontrolled asthma, the greatest wish is to live without the constant fear of the next exacerbation, hospitalization, or another course of systemic corticosteroids. When standard therapy is no longer sufficient, we look for new ways to help our patients. Clinical trials make it possible to evaluate innovative treatment approaches and bring them closer to those who need them most,” said Kseniia Sekretna, Head of the Clinical Research Center at Dobrobut Medical Network and pulmonologist.

The study is open to adults aged 18 to 80 years with a confirmed diagnosis of bronchial asthma for at least two years who continue to have severe uncontrolled disease despite treatment with medium- or high-dose inhaled corticosteroids combined with at least one additional controller medication. Participants should also have experienced at least two asthma exacerbations requiring systemic corticosteroid treatment within the previous 12 months, weigh at least 40 kg, and meet all other protocol-defined eligibility criteria determined during screening.

Participation may not be possible for individuals with clinically significant active infections, certain concomitant diseases, lung function values that do not meet protocol requirements, or other exclusion criteria specified in the study protocol.

All participants will receive continuous supervision by the study team, access to the investigational biologic therapy, free physician consultations, laboratory and instrumental examinations, regular disease monitoring, transportation to the clinical site, and meals during study visits.

Participant safety is the study's highest priority. Every candidate undergoes a comprehensive screening evaluation before enrollment, and participation is confirmed only after all protocol eligibility criteria have been met. Participation is entirely voluntary, and participants may withdraw from the study at any time.

Patients from all regions of Ukraine are welcome to participate.

The study is conducted in accordance with the International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines, the current legislation of Ukraine, and following approval by the State Expert Center of the Ministry of Health of Ukraine and the Ethics Committee.

For more information or to schedule a preliminary consultation, please call +380 67 150 29 87 (Olha Zhmurko, Clinical Research Manager at Dobrobut Medical Network) or contact us via messaging apps.